Unity Biotechnology Overview

  • Founded
  • 2009

Founded
  • Status
  • Public

  • Employees
  • 65

Employees
  • Stock Symbol
  • UBX

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $1.37

  • (As of Tuesday Closing)

Unity Biotechnology General Information

Description

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells; and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases.

Contact Information

Formerly Known As
Cenexys
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 285 East Grand Avenue
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Unity Biotechnology Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.37 $1.29 $0.55 - $3.64 $89.8M 69.7M 2.46M -$0.95

Unity Biotechnology Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 11,048 59,209 204,996 218,266
Revenue 5,020 4,784 0 0
EBITDA (53,385) (54,748) (90,299) (82,766)
Net Income (59,195) (60,725) (93,844) (82,177)
Total Assets 97,593 124,712 156,319 151,221
Total Debt 48,330 55,936 63,496 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Unity Biotechnology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Unity Biotechnology‘s full profile, request access.

Request a free trial

Unity Biotechnology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Unity Biotechnology‘s full profile, request access.

Request a free trial

Unity Biotechnology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focu
Biotechnology
South San Francisco, CA
65 As of 2021
00000
000000 - 000 00000

000000

is nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate veli
0000000000000
Alameda, CA
000.00
0000000000 000.00

00000

iam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute ir
0000 000000000
Seattle, WA
00 As of 0000
00.00
0000000000 0 00.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Unity Biotechnology Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Recyte Therapeutics Angel-Backed Alameda, CA 000.00 0000000000 000.00
00000 000000000000 Venture Capital-Backed Seattle, WA 00 00.00 0000000000 0 00.00
0000 000000000000 Venture Capital-Backed Chicago, IL 0 000 0000000000 000
000000 Formerly VC-backed Honolulu, HI 00 000.00 000000000 000.00
To view Unity Biotechnology’s complete competitors history, request access »

Unity Biotechnology Patents

Unity Biotechnology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020385991-A1 Antibodies directed to tie-2 and methods of use Pending 21-Nov-2019 00000000000
CA-3162181-A1 Antibodies directed to tie-2 and methods of use Pending 21-Nov-2019 000000000
US-20210155697-A1 Antibodies directed to tie-2 and methods of use Pending 21-Nov-2019 000000000
US-20210379078-A1 Killing senescent cells and treating senescence-associated conditions using a bcl inhibitor and an mcl-1 inhibitor Abandoned 30-Oct-2018 000000000
US-20190382371-A1 Acyl sulfonamides that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer Granted 13-Jun-2018 C07D401/10
To view Unity Biotechnology’s complete patent history, request access »

Unity Biotechnology Executive Team (23)

Name Title Board Seat Contact Info
Anirvan Ghosh Ph.D Chief Executive Officer & Board Member
Lynne Sullivan Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Susan Lundeen Chief Human Resources Officer
Przemyslaw Sapieha Ph.D Chief Scientific Officer
Daohong Zhou MD Co-Founder
You’re viewing 5 of 23 executive team members. Get the full list »

Unity Biotechnology Board Members (11)

Name Representing Role Since
Anirvan Ghosh Ph.D Unity Biotechnology Chief Executive Officer & Board Member 000 0000
Camille Samuels Venrock Board Member and Member of Audit Committee 000 0000
Keith Leonard Jr. Unity Biotechnology Chairman 000 0000
Margo Roberts Ph.D Unity Biotechnology Board Member and Member of Nominating and Corporate Governance Committee and Science Committee 000 0000
Michael Samar Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Unity Biotechnology Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Unity Biotechnology Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Unity Biotechnology‘s full profile, request access.

Request a free trial

Unity Biotechnology Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 01-Feb-2016 00000 0000 Media and Information Services (B2B)
To view Unity Biotechnology’s complete investments history, request access »